Tbilisi, Georgia – BioChimPharm, a Georgian biopharmaceutical company, announces the completion of the modernization and renovation of its historic phage manufacturing facility, which was originally built in 1934. The facility, which is fully dedicated to R&D and the production of bacteriophage-based medications, has been updated to comply with EU GMP (Good Manufacturing Practice) guidelines, an internationally recognized standard.
The two-year investment project, worth €6,000,000, is a significant step in BioChimPharm’s mission to provide access to phage therapy on a global scale and combat the growing threat of antibiotic resistance. It also highlights Georgia’s important role in the history and development of phage technology.
The modernization of the manufacturing plant, high-tech infrastructure and production lines enables BioChimPharm to scale-up its production, making bacteriophages available for millions of patients who suffer from antibiotic resistant infections across the globe. Since phage therapy is new to many countries, this renovation will allow for increased production capacity and expanded export capabilities.
“Millions of people still do not have access to phages, leaving patients vulnerable to antibiotic-resistant infections,” said Rati Golijashvili, the general manager of BioChimPharm. “With this project, the company is increasing its production capacity and export area, thus making bacteriophages available for millions of patients across the globe. The modernization of the manufacturing plant with high-tech infrastructure and production lines will enable BioChimPharm to scale-up its production in compliance with internationally recognized manufacturing standards, to become more effective in fight against the resistant infections, and to overcome the global threat of antibiotic resistance.”
BioChimPharm and Phage therapy
Phages are a tiny, hundred times smaller microorganisms that infect and kill bacteria and they, have been found to be highly effective against antibiotic-resistant bacterial strains.
BioChimPharm has developed a range of breakthrough products that utilizes this technology to provide an alternative to traditional antibiotics and effectively treat antibiotic-resistant infections. These products represent a significant advancement in the fight against antibiotic resistance (AMR). Georgia besides being a pioneer and the world-renowned for its 8,000-year-old tradition of winemaking, it also happens to be a cradle of Phage technology and Phage Therapy. The Country has a rich history in the development of phage technology, with early research and discoveries dating back to the early 20th century. With this newly modernized manufacturing plant, BioChimPharm continues to contribute to the advancement of phage technology and improve access to phage therapy for patients globally.
With nearly 100 years of experience in phage R&D and production, BioChimPharm’s mission is to cut the overuse of antibiotics in the human and animal health industries and to overcome antibiotic resistant infections globally. The newly modernized manufacturing plant is located in the historic Bacteriophage Institute in the heart of Tbilisi, Georgia, and is the first enterprise producing sterile liquid dosage forms in the South Caucasus, covering the full production cycle, including the production of active pharmaceutical ingredients (APIs) and primary and secondary packaging of medicines.
For more information, please contact BioChimPharm at firstname.lastname@example.org.